Rhythm Pharmaceuticals Inc
Închisă
SectorSănătate
102.76 -1.78
Rezumat
Modificarea prețului
24h
Minim
103.67
Maxim
106.1
Venit | -49M -105M |
|---|---|
Vânzări | 11M 71M |
EPS | -0.73 |
Marjă de profit | -147.27 |
Angajați | 414 |
EBITDA | 6.2M -44M |
Următoarele câștiguri | 3 nov. 2026 |
|---|
Capitalizare de piață | 24M 7.1B |
|---|---|
Deschiderea anterioară | 104.54 |
Închiderea anterioară | 102.76 |
Sentimentul știrilor
By Acuity
64%
36%
285 / 339 Clasament în Healthcare
Rhythm Pharmaceuticals Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Rhythm Pharmaceuticals Inc Așteptări
Sentiment
By Acuity
285 / 339 Clasament în Sănătate
Sentimentul știrilor
Evidențe de scădere
Volatilitate
Sub medie
Volumul știrilor (RCV)
Sub medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.